האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

eli lilly nederland b.v. - raloksifenhydroklorid - osteoporose, postmenopausale - sex hormoner og modulatorer av genital systemet, - optruma er indisert for behandling og forebygging av osteoporose hos postmenopausal kvinner. en signifikant reduksjon i forekomsten av vertebrale, men ikke hoftefrakturer har blitt påvist. når valget av optruma eller andre behandlinger, inkludert østrogen, for en individuell postmenopausale kvinne, vurdering bør gis til menopausal symptomer, effekter på livmor og bryst vev, og kardiovaskulær risiko og fordeler (se del 5.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

teva b.v. - raloksifenhydroklorid - osteoporose, postmenopausale - sex hormoner og modulatorer av genital systemet, - raloksifen er indisert for behandling og forebygging av osteoporose hos postmenopausale kvinner. en signifikant reduksjon i forekomsten av vertebrale, men ikke hoftefrakturer har blitt påvist. når du skal bestemme valg av raloxifene eller andre behandlingsformer, inkludert oestrogens, for en individuell postmenopausale kvinner, og det bør vurderes å menopausal symptomer, effekter på livmor og bryst vev, og kardiovaskulær risiko og fordeler.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

shionogi b.v. - ospemifen - postmenopause menopause~~pos=headcomp - sex hormoner og modulatorer av genital systemet, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuvant behandling av melanomadabrafenib i kombinasjon med trametinib er indikert for adjuvant behandling av voksne pasienter med stadium iii melanom med en braf v600 mutasjon, følgende komplett reseksjon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

נורווגיה - נורבגית - Statens legemiddelverk

eumedica pharmaceuticals gmbh - sulfametoksazol / trimetoprim - mikstur, suspensjon - 40 mg/ ml / 8 mg/ ml

נורווגיה - נורבגית - Statens legemiddelverk

eumedica pharmaceuticals gmbh - sulfametoksazol / trimetoprim - tablett - 400 mg / 80 mg

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiske midler - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

pierre fabre medicament - binimetinib - melanom - antineoplastiske midler - binimetinib i kombinasjon med encorafenib er indisert for behandling av voksne pasienter med inoperabel eller metastatisk melanom med en braf v600 mutasjon.

נורווגיה - נורבגית - Statens legemiddelverk

novartis norge as - triamcinolonacetonid - injeksjonsvæske, suspensjon - 40 mg/ ml